Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial

IMPORTANCE: Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant approach is warranted. OBJECTIVE: To evaluate the margin-negative (R0) resection rate of neoadjuvant FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Oncol
Päätekijät: Murphy, Janet E., Wo, Jennifer Y., Ryan, David P., Clark, Jeffrey W., Jiang, Wenqing, Yeap, Beow Y., Drapek, Lorraine C., Ly, Leilana, Baglini, Christian V., Blaszkowsky, Lawrence S., Ferrone, Cristina R., Parikh, Aparna R., Weekes, Colin D., Nipp, Ryan D., Kwak, Eunice L., Allen, Jill N., Corcoran, Ryan B., Ting, David T., Faris, Jason E., Zhu, Andrew X., Goyal, Lipika, Berger, David L., Qadan, Motaz, Lillemoe, Keith D., Talele, Nilesh, Jain, Rakesh K., DeLaney, Thomas F., Duda, Dan G., Boucher, Yves, Fernández-Del Castillo, Carlos, Hong, Theodore S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2019
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547247/
https://ncbi.nlm.nih.gov/pubmed/31145418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0892
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia